200435-92-3

Basic information

• Product Name: 1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione
• Synonyms: 1-(2'-O,4-C-Methylene-beta-D-ribofuranosyl)uridine;1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione;1-(2'-O 4-C-Methylene-b-D-ribofuranosyl)uridine;1-(2'-O, 4-C-Methylene-β-D- ribofuranosyl)uridine;1-[2,5-Anhydro-4-(hydroxymethyl)-α-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione;2'-O,4'-C-Methyleneuridine
• CAS NO: 200435-92-3
• Molecular Formula: C₁₀H₁₂N₂O₆
• Molecular Weight: 256.213
• Mol File: 200435-92-3.mol

Chemical Properties

• Melting Point: 239-243 °C(Solv: methanol (67-56-1))
• Appearance: /
• Density: 1.695
• PKA: 9.30±0.10(Predicted)
• CAS DataBase Reference: 1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione(200435-92-3)
• EPA Substance Registry System: 1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione(200435-92-3)

Safety Data

• Hazardous Substances Data: 200435-92-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione is used as a bridged nucleic acid for high binding affinities to DNA and RNA when paired with a phenoxazine base. This property makes it a valuable compound for the development of new drugs and therapies, particularly in the field of molecular biology and genetics.
Used in Diagnostic Applications:
Due to its high binding affinity to DNA and RNA, 1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione can be utilized in the development of diagnostic tools and techniques. It may be employed in the creation of more accurate and sensitive tests for detecting genetic disorders, viral infections, and other conditions related to nucleic acid interactions.
Used in Research and Development:
The unique properties of 1-[2,5-Anhydro-4-C-(hydroxymethyl)-alpha-L-lyxofuranosyl]-2,4(1H,3H)-pyrimidinedione make it an interesting compound for research and development in various scientific fields. It can be used to study the interactions between nucleic acids and other molecules, as well as to develop new methods for manipulating genetic material.

Upstream product

• 200435-91-2 1-((1S,3R,4R,7S)-7-(benzyloxy)-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl)pyrimidine-2,4(1H,3H)-dione 
• 1094603-23-2 ((1R,3R,4R,7S)-7-(benzyloxy)-3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dioxabicyclo[2.2.1]heptan-1-yl)methyl benzoate 
• 1094603-22-1 ((1R,3R,4R,7S)-7-(benzyloxy)-3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dioxabicyclo[2.2.1]heptan-1-yl)methyl methanesulfonate 
• 1094603-21-0 (2R,3R,4S)-4-(benzyloxy)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-5,5-bis(((methylsulfonyl)oxy)methyl)tetrahydrofuran-3-yl acetate 
• 293751-03-8 1,2-di-O-acetyl-3-O-benzyl-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl-D-erythro-pentofuranose 
• 293751-01-6 3-O-benzyl-4-C-methanesulfonoxymethyl-5-methanesulfonyl-1,2-O-isopropylidene-α-D-erythro-pentofuranose 
• 956485-08-8 ((3aR,5R,6S,6aR)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-6-(naphthalen-2-ylmethoxy)tetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 956485-07-7 ((3aR,6S,6aR)-2,2-dimethyl-6-(naphthalen-2-ylmethoxy)tetrahydrofuro[3,2-d][1,3]dioxole-5,5-diyl)dimethanol 
• 1057385-93-9 (3aR,5S,6R,6aR)-2,2-dimethyl-6-(naphthalen-2-ylmethoxy)tetrahydrofuro[3,2-d][1,3]dioxole-5-carbaldehyde 
• 1070968-94-3 C₂₀H₂₄O₆ 
• 620630-82-2 1,2 5,6-O-di(isopropylidene)-α-D-allofuranose 
• 1174917-58-8 C₃₇H₄₄O₈SSi 
• 1174917-62-4 C₂₆H₃₀N₂O₆Si 
• 1174917-61-3 C₃₇H₃₈N₂O₆Si 

Downstream Products

• 206055-67-6 (1S,3R,4R,7S)-7-hydroxy-1-hydroxymethyl-(thymin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane 
• 206055-71-2 1-[(1R,4R,6R,7S)-4-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-5-methylpyrimidine-2,4-dione 
• 206055-75-6 (1R,3R,4R,7S)-3-(thymine-1-yl)-1-(4,4′-dimethoxytrityloxy)-7-(2-cyanoethoxy(diisopropylamino)phosphinoxymethyl)-2,5-dioxabicyclo[2.2.1]heptane 
• 206055-76-7 5′-O-(4,4′-dimethoxytrityl)-2′-O,4′-C-methylenethymidine-3′-[O-(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite 
• 1314716-25-0 C₃₄H₃₁N₃O₈S 
• 1314716-26-1 C₄₃H₄₈N₅O₉PS 
• 1314716-27-2 C₄₀H₄₅N₃O₈SSi 
• 1314716-28-3 C₄₇H₅₀N₄O₈SSi 
• 1314716-29-4 C₄₁H₃₆N₄O₈S 
• 1314716-30-7 C₅₀H₅₃N₆O₉PS 
• 1275611-00-1 (1R,3R,4R,7S)-3-[5-(3-benzoyloxypropyn-1-yl)uracil-1-yl]-1-(4,4′-dimethoxytrityloxymethyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptane 

Relevant articles and documents

Chemoenzymatic convergent synthesis of 2'-o,4'-c-methyleneribonucleosides

Novozyme-435-catalyzed efficient regioselective acetylation of one of the two diastereotopic hydroxymethyl functions in 3-O-benzyl-4-C-hydroxymethyl-1,2- O-isopropylidene-α-d-ribofuranose has been achieved. The enzymatic methodology has been successfully

Synthesis of 2′-O,4′-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase

The synthesis of 2′-O,4′-C-methylene-bridged bicyclic guanine ribonucleosides bearing 2′-C-methyl or 5′-C-methyl modifications is described. Key to the successful installation of the methyl functionality in both cases was the use of a one-pot oxidation-Grignard procedure to avoid formation of the respective unreactive hydrates prior to alkylation. The 2′-C-methyl- and 5′-C-methyl-modified bicyclic guanosines were evaluated, along with the known uracil-, cytosine-, adenine-, guanine-LNA and guanine-ENA nucleosides, as potential antiviral agents and found to be inactive in the hepatitis C virus (HCV) cell-based replicon assay. Examination of the corresponding nucleoside triphosphates, however, against the purified HCV NS5B polymerase indicated that LNA-G and 2′-C-methyl-LNA-G are potent inhibitors of both 1b wild type and S282T mutant enzymes in vitro. Activity was further demonstrated for the LNA-G-triphosphate against HCV NS5B polymerase genotypes 1a, 2a, 3a and 4a. A phosphorylation by-pass prodrug strategy may be required to promote anti-HCV activity in the replicon assay.

BASE MODIFIED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Provided herein are novel base modified bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel pyrimidine bicyclic nucleosides are provided wherein each pyrimidine base is subs

Optimized synthesis of LNA uracil nucleosides

A short, very high yielding, and practical synthesis of LNA uracil diol 6 has been developed from the easily accessible glycosyl donor 1. The concluding O3′-debenzylation of 5 resulted in significant reduction of the uracil moiety with many typical debenz

IMPROVED SYNTHESIS OF ?2.2.1|BICYCLO NUCLEOSIDES

A synthesis of [2.2.1]bicyclo nucleosides which is shorter and provides higher overall yields proceeds via the key intermediate of the general formula III, wherein R4 and R5 are, for instance, sulfonates and R7 is, for instance, a halogen or an acetate. F

Bicyclonucleoside and oligonucleotide analogue

An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

Novel bicyclonucleoside and oligonucleotide analogue

An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

2'-O,4'-C-Methylene bridged nucleic acid (2',4'-BNA): synthesis and triplex-forming properties.

For development of ideal antisense and antigene molecules, various chemical modifications of oligonucleotides have been studied. However, despite their importance, there is only limited information available on the triplex-forming ability of the conformat

Bicyclonucleoside and oligonucleotide analogues

An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

DNA triplex structures are stabilized by the incorporation of 3'-endo blocked pyrimidine nucleosides in the hoogsteen strand

A short route to pyrimidine locked nucleosides has been developed for their incorporation in triplex forming oligonucleotides (TFO). Compared to oligonucleotides built with standard nucleosides, the modified TFOs containing 3'-endo blocked residues formed